| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Protein argonaute-2 ;Argonaute2 ;hAgo2;3.1.26.n2 ;Argonaute RISC catalytic component 2;Eukaryotic translation initiation factor 2C 2 ;eIF-2C 2 ;eIF2C 2 ;PAZ Piwi domain protein;PPD;Protein slicer ;AGO2;EIF2C2; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human Argonaute 2 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-AGO2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AODE-1; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, IP, Flow (as provided in the source record). Boster Bio Anti-Argonaute 2 AGO2 Rabbit Monoclonal Antibody catalog # M00189. Tested in WB, IHC, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: AGO2 (Protein argonaute-2).
- Antibody format: Monoclonal; clone AODE-1; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
AGO2 (protein: P2X purinoceptor 1) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The 'minimal RISC' appears to include AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). These guide RNAs RISC to complementary mRNAs that are targets for RISC-mediated gene silencing. The precise mechanism of gene silencing depends on the degree of complementarity between the miRNA or siRNA and its target. Binding of RISC to a perfectly complementary mRNA generally results in silencing due to endonucleolytic cleavage of the mRNA specifically by AGO2. Binding of RISC to a partially complementary mRNA results in silencing through inhibition of translation, and this is independent of endonuclease activity. May inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. May also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. The inhibition of translational initiation leads to the accumulation of the affected mRNA in cytoplasmic processing bodies (P-bodies), where mRNA degradation may subsequently occur. In some cases RISC-mediated translational repression is also observed for miRNAs that perfectly match the 3' untranslated region (3'-UTR). Can also up-regulate the translation of specific mRNAs under certain growth conditions. Binds to the AU element of the 3'-UTR of the TNF (TNF-alpha) mRNA and up-regulates translation under conditions of serum starvation. Also required for transcriptional gene silencing (TGS), in which short RNAs known as antigene RNAs or agRNAs the transcriptional repression of complementary promoter regions. . Reported cellular localization context: Cytoplasm, P-body. Nucleus. Translational repression of mRNAs results in their recruitment to P-bodies. Translocation to the nucleus requires IMP8. Tissue expression notes (as provided): Expressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform 7 is expressed in tumor cells only. .
Research relevance and current trends
- Research context keywords from the source record include: 2339,DNA/RNA,Epigenetics and Nuclear Signaling,Nuclear Receptors,Nuclear Signaling Pathways,RNA Processing.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
- Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.
Workflow ideas (metafield): Validate AGO2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect AGO2 expression by Western blot in cell or tissue lysates, Detect AGO2 in FFPE tissue sections by immunohistochemistry, Localize AGO2 by immunofluorescence/immunocytochemistry in cultured cells, Quantify AGO2-positive cells by flow cytometry in single-cell suspensions, Enrich AGO2 by immunoprecipitation from lysates for downstream analysis
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 97 kDa; calculated MW: 97208 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 97 kDa
- Cellular localization (provided): Cytoplasm, P-body. Nucleus. Translational repression of mRNAs results in their recruitment to P-bodies. Translocation to the nucleus requires IMP8.
- Tissue details (provided): Expressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform 7 is expressed in tumor cells only. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
